Podcasts about Squamous cell carcinoma

Send me a question or story!Solar dermatitis (actinic keratosis) is skin damage from prolonged UV exposure, affecting both dogs and cats, particularly those with light-colored or thin coats. So, pets that have white fur and live in high UV exposure areas (like the southern US) are predisposed. Symptoms include redness, scaling, hair loss, and thickened, crusty skin. Commonly affected areas include the nose, ears, abdomen, and inner thighs. This condition can lead to more severe issues, including pre-cancerous lesions and aggressive skin cancer like squamous cell carcinoma. We will discuss ways to identify this disease and treatment options such as CO2 laser ablation, etc.00:00 – Intro04:06 – Nasal Solar Dermatitis06:32 – Classic Canine Solar Dermatitis08:15 – Treatment Options for Solar Dermatitis16:52 – Outro

Dr. Vernon Sondak discusses two common types of skin cancer: basal and squamous cell. He details their characteristics and statistics.

My granddaughter suffers from menstrual cramps.  Do you have any suggestions?Do you recommend nicotinamide daily to prevent recurrence of basal cell cancers?What works best to lower fibrinogen?I've been on Ozempic for a year and have diarrhea every morning!Is bypass surgery still being done?Would you recommend Bergamot for fatty liver?

Thanksgiving and overindulgenceA food poisoning incidentObservations on health at ThanksgivingWhat do you think of online sites offering prescriptions for hair loss via a questionnaire?

In this episode, Kelly Knickelbein, VMD, DACVO, joined us to discuss ocular squamous cell carcinoma in horses, including clinical signs, risk factors, treatment options, prevention strategies, and more. She also briefly discussed her current research on genetic cataracts in horses. This episode of Disease Du Jour is brought to you by Equithrive.GUESTS AND LINKS - EPISODE 169Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)Guest: Dr. Kelly Knickelbein, VMD, DACVOPodcast Website: Disease Du JourThis episode of Disease Du Jour podcast is brought to you by Equithrive.Connect with the Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)

In this episode, Kelly Knickelbein, VMD, DACVO, joined us to discuss ocular squamous cell carcinoma in horses, including clinical signs, risk factors, treatment options, prevention strategies, and more. She also briefly discussed her current research on genetic cataracts in horses. This episode of Disease Du Jour is brought to you by Equithrive.GUESTS AND LINKS - EPISODE 169Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)Guest: Dr. Kelly Knickelbein, VMD, DACVOPodcast Website: Disease Du JourThis episode of Disease Du Jour podcast is brought to you by Equithrive.Connect with the Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)

In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including:Trials of neoadjuvant immunotherapies demonstrating remarkable response rates with PD-(L)1 inhibitors such as cemiplimab, pembrolizumab, atezolizumab, and nivolumab with or without ipilimumabOngoing investigational efforts, including the phase III CLEAR CSCC study of intralesional immunotherapy and radiation-immunotherapy sequencingPresenters:David M. Miller, MD, PhD, FAADDirector, Center for Merkel Cell CarcinomaCo-Director, NMSC Multi-Disciplinary ClinicMassachusetts General Cancer CenterAssistant Professor of Medicine and DermatologyHarvard Medical SchoolBoston, MassachusettsVishal Anil Patel, MDDirector of Cutaneous Oncology, GW Cancer CenterDirector of Dermatologic Surgery, GW Department of DermatologyAssociate Professor of Dermatology & of Medicine (Hematology/Oncology)George Washington University School of Medicine & Health SciencesWashington, DCLink to full program: https://bit.ly/3JbflO3 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.

Editor-in-Chief Cecelia E. Schmalbach, MD, MSc is joined by author Omar Karadaghy, MD, MSCI, and Associate Editor Sean Massa, MD, to discuss impact of surgical margin status in HPV-related oropharyngeal squamous cell carcinoma in "Impact of Margins on Outcomes in HPV-Related Oropharyngeal Squamous Cell Carcinoma Treated With Surgery Only,” which published in the July 2025 issue of Otolaryngology–Head and Neck Surgery. They talk about the potential for improved patient care by re-examining the standards for surgical margins. Click here to read the full article.

Please visit answersincme.com/VJW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cutaneous oncology discuss the role of emerging immunotherapeutic strategies in treating resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review the current guideline-recommended use of immunotherapies for the management of resectable CSCC; Identify clinical factors that will guide the use of immunotherapeutic approaches for patients with resectable CSCC; Outline proactive strategies to enhance the benefit-to-risk profile of immunotherapy for patients with resectable CSCC; and Describe the evolving role of novel applications of immunotherapy in the treatment of resectable CSCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/VJW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cutaneous oncology discuss the role of emerging immunotherapeutic strategies in treating resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review the current guideline-recommended use of immunotherapies for the management of resectable CSCC; Identify clinical factors that will guide the use of immunotherapeutic approaches for patients with resectable CSCC; Outline proactive strategies to enhance the benefit-to-risk profile of immunotherapy for patients with resectable CSCC; and Describe the evolving role of novel applications of immunotherapy in the treatment of resectable CSCC. This activity is intended for US healthcare professionals only.

  This article surveys several malignancies that can occur in the oral cavity—from salivary gland tumors to sarcomas—to highlight their presentations, pathology, and management. Andreina Sucre, MSc, RDH Read by Jackie Sanders  https://www.rdhmag.com/pathology/article/55271904/beyond-squamous-cell-carcinoma-a-spectrum-of-oral-cavity-malignancies 

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

Interview with Kevin J. Contrera, MD, MPH, author of Neoadjuvant Therapy for Mucosal Head and Neck Squamous Cell Carcinoma: A Review From the American Head and Neck Society. Hosted by Paul C. Bryson, MD, MBA. Related Content: Neoadjuvant Therapy for Mucosal Head and Neck Squamous Cell Carcinoma

Interview with Kevin J. Contrera, MD, MPH, author of Neoadjuvant Therapy for Mucosal Head and Neck Squamous Cell Carcinoma: A Review From the American Head and Neck Society. Hosted by Paul C. Bryson, MD, MBA. Related Content: Neoadjuvant Therapy for Mucosal Head and Neck Squamous Cell Carcinoma

Diagnosis and management of nail unit squamous cell carcinoma: a clinical review by an expert panel.Curtis KL, Amin SP, Jellinek NJ, Knackstedt TJ, Miller CJ, Piraccini BM, Richert B, Rubin AI, Trakatelli MG, Lipner SR. JAAD Reviews. 2024 Dec 31.Evaluation and diagnosis of longitudinal melanonychia: A clinical review by a nail expert group.Ricardo JW, Bellet JS, Jellinek N, Lee D, Miller CJ, Piraccini BM, Richert B, Rubin AI, Lipner SR.Journal of the American Academy of Dermatology. 2025 Feb 27.

This DermSurgery Digest bonus content aptly named “At the Microscope” shares the latest research and techniques in dermatopathology. In this episode, contributors will review the topic of perineural invasion in squamous cell carcinoma. Contributors to this podcast include Naomi Lawrence, MD, Dermatologic Surgery Digital Content Editor; Ashley Elsensohn, MD, MPH, DermSurgery Digest at the Microscope co-host; Christine Ahn, MD; Jeff Gardner, MD; Marina K. Ibraheim, MD; and Michael P. Lee, MD.Articles featured in this episode include:  Carter JB, Johnson MM, Chua TL, Karia PS, Schmults CD. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol. 2013 Jan;149(1):35-41. doi: 10.1001/jamadermatol.2013.746. PMID: 23324754 Link: https://pubmed.ncbi.nlm.nih.gov/23324754/Conde-Ferreirós A, Corchete LA, Jaka A, Santos-Briz Á, Fuente MJ, Posada R, Pons L, Podlipnik S, Pujol RM, Román-Curto C, Toll A, Cañueto J. Patterns of incidental perineural invasion and prognosis in cutaneous squamous cell carcinoma: A multicenter, retrospective cohort study. J Am Acad Dermatol. 2021 Jun;84(6):1708- 1712. doi: 10.1016/j.jaad.2020.08.017. Epub 2020 Aug 8. PMID: 32781186. Link: https://pubmed.ncbi.nlm.nih.gov/32781186/ Harvey NT, Palmer DJ, Tucker P, Chakera A, Foster R, Lim W, Trevithick RW, Wood BA. Histological predictors of outcome for cutaneous squamous cell carcinoma in renal transplant patients: A case-control study. JAAD Int. 2023 Dec 29;15:51-58. doi: 10.1016/j.jdin.2023.11.010. PMID: 38371661; PMCID: PMC10869928. Link: https://pubmed.ncbi.nlm.nih.gov/38371661/ Massey PR, Wang DM, Murad F, Mulvaney P, Moore K, Okhovat JP, Russell- Goldman E, Lin WM, Piris A, Huilgol SC, Ruiz ES, Schmults CD. Extensive Perineural Invasion vs Nerve Caliber to Assess Cutaneous Squamous Cell Carcinoma Prognosis. JAMA Dermatol. 2023 Dec 1;159(12):1332-1338. doi: 10.1001/jamadermatol.2023.3703. PMID: 37851425; PMCID: PMC10585586. Link: https://pubmed.ncbi.nlm.nih.gov/37851425/ Your feedback is encouraged. Please contact communicationstaff@asds.net.

In this PRO podcast, Bisham Chera MD, FASTRO, Danielle Margalit, MD, MPH, and David Sher, MD, discuss the recently published ASTRO clinical practice guideline of Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma. This manuscript was published in print in the September/October 2024 issue and was the 3rd most downloaded PRO article in 2024. Listen for their lively and meaningful discussion of the key recommendations and controversies.

Dr. Chris Holsinger shares the new guideline from ASCO on transoral robotic surgery (TORS) for patients with oropharyngeal squamous cell carcinoma. He reviews the evidence-based recommendations on baseline assessment, the role of TORS in HPV-positive and HPV-negative disease and in the salvage/recurrent setting, which patients are eligible or ineligible for TORS, and the role of adjuvant therapy. He discusses the importance of multidisciplinary collaboration and shared decision-making between patients and their clinicians. Read the full guideline, “Transoral Robotic Surgery in the Multidisciplinary Care of Patients with Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline.”   TRANSCRIPT This guideline, clinical tools, and resources are available at asco.org. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology.   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts, delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts.    My name is Brittany Harvey and today I'm interviewing Dr. Chris Holsinger from Stanford University, lead author on “Transoral Robotic Surgery in the Multidisciplinary Care of Patients with Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline.” Thank you for being here today, Dr. Holsinger. Dr. Chris Holsinger: Thanks, Brittany. We've been working together for years on these guidelines and what a pleasure to get to meet you at least virtually today. Brittany Harvey: Yes, it's great to have you on. And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Holsinger, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So let's jump into this important guideline. Dr. Holsinger, to start us off, can you provide an overview of both the scope and purpose of this guideline? Dr. Chris Holsinger: Absolutely. And again, thanks for the opportunity to be here, Brittany. I appreciate the invitation to participate in the ASCO Guidelines and to work with the great people on this paper that's now out there. I think it's a really important guideline to be published because it really talks about surgery, specifically transoral robotic surgery, a minimally invasive technique, as a new way to treat head and neck cancer. Why that's so important is that what is now known as head and neck cancer is completely different than what we saw even 25 years ago. Around the turn of the century, some really thoughtful epidemiologists working at Hopkins and UW in Seattle started to see this connection between the human papillomavirus and head and neck cancer. And since then we've seen this precipitous rise in the number of throat cancers specifically due to HPV. The results from the American Cancer Society showed last year that head neck cancer, in particular these cancers of the oropharynx, actually were one of the few cancers that still had an increasing incidence, I think it was around 2.5% per year. And other studies have shown that almost 50% of the cases we're seeing across the United States now are actually HPV-mediated throat cancers. That's bad news because we're seeing this rise in cases, but it's good news in the sense that this is a cancer that is highly curable and I think opens up a lot of different treatment avenues that we didn't have a couple of decades ago. And when patients are facing a mortality risk that's two or three times lower than the formerly HPV-negative smoking-driven cancers, it really behooves us as clinicians, as oncologists to think about treatment selection in a completely different way. And for years, the only function-sparing option, surgery certainly was not, was radiation therapy with concurrent cisplatin chemotherapy. In 2009, the FDA approved the use of surgical robotics using a transoral approach, a minimally invasive approach to resect the primary tumors and to perform neck dissection. And so now when patients walk in the door, they not only have this gold standard option in the path of radiation therapy with chemo, but also frontline surgery. And with some recent publications, especially the ECOG 3311 study, there's some really good evidence that for HPV-mediated throat cancers, we can actually de-escalate the intensity of adjuvant therapy when we start with surgery first. So who we choose that option for, which patients want that option - these are all really important new questions that we try to grapple with in these guidelines. Brittany Harvey: That background is really key for setting the stage for what we're about to talk about today. And so next I'd like to review the key recommendations across the clinical questions that the panel addressed. So you just talked about the importance of treatment selection. So to start that off, first, what is recommended for baseline assessment for patients with oropharyngeal squamous cell carcinoma who are being considered for transoral robotic surgery? Dr. Chris Holsinger: So I think here we tried in the guidelines to really standardize the workup and approach of this disease, in general, but with a strong focus on who might be a good surgical candidate. As I mentioned in the introduction, I mean, this is a disease that is very new. Our workup is in flux. And so what we tried to do, especially in items 1.2 and 1.3, is to really standardize and confirm that the tumor that we're dealing with, which oftentimes presents in a metastatic lymph node, is in fact associated with the human papillomavirus. So how biopsy is done, how high risk HPV testing is performed, whether you're doing that with an in situ hybridization, a DNA based study, or a p16 immunohistochemical study. And we try to tackle these issues first to really make sure that the patient population we're considering is actually indeed eligible for this kind of treatment de-escalation with surgery. Brittany Harvey: Understood. So it's important to consider which patients could be eligible for TORS upfront. So what is the role of TORS in patients with HPV-positive oropharyngeal squamous cell carcinoma? Dr. Chris Holsinger: Yeah, exactly. So I think first of all, surgery is ideally suited, and the robot is FDA approved for early-stage cancers - T1 and T2 cancers that are amenable to a minimally invasive approach. And we really try to emphasize, especially in our patient selection section of the guideline, who is really an ideal candidate for this. It's not just the T1 and T2 tumor. It's a tumor that is lateralized so that we can maybe consider managing the neck concurrently just on the side of the tumor, rather than doing bilateral neck dissection for most patients. Which patients might get the best functional outcome is a really critical component of this. And in fact, that actually goes back to a guideline that we didn't have time to chat about earlier, which is that we think every head neck cancer patient, whether or not they're being considered for transoral robotic surgery or frontline radiation therapy with cisplatin, every patient should have a pre-treatment assessment by a speech and swallowing expert. They're called different names across the country: speech language pathologists, speech pathologists, etc. But having a really good functional assessment of the patient's ability to swallow before treatment selection is really critical. And why that's important with frontline surgery is that there's a period of about one or two weeks after which that patient really needs intensive rehabilitation. And so for every patient being considered by TORS, we want to work really hand in hand with that speech pathologist to do pre-habilitation and then immediate post-operative rehab and then long longitudinal rehabilitation so that if radiation is needed down the road in a month, that patient just hopefully sails through this de-escalated treatment that we're offering. Brittany Harvey: Great. I appreciate you describing which patients can be considered for transoral robotic surgery. So beyond that, which patients with HPV-positive oropharyngeal squamous cell carcinoma aren't really good candidates for TORS? Dr. Chris Holsinger: We talked about that sort of ideal patient, but you know, we're not always living in an ideal world. And so I think it's important, and I'm really happy about the multidisciplinary discussions that led to these final guidelines because I think it helped engage radiation oncologists, medical oncologists, and surgeons around who's maybe not a good candidate for this because radiation therapy, with or without cisplatin chemotherapy, remains a good option for many of these patients. But I think the consensus, especially among the surgeons in this group, were that patients with tumors were more endophytic - that's the old fashioned oncology and surgical oncology term that refers to tumors that seem to not be as evident on the surface and have more of an infiltrative deep growth pattern - these are not ideal tumors. Whereas an exophytic tumor that's growing upwards, that's more readily seen on flexible endoscopy during a routine clinic assessment, or frankly, better seen on imaging, those exophytic tumors are better suited to a surgical approach because the surgeon has a better chance when he or she sees the tumor to get a good margin. When we can appreciate not just the surface mucosal margins that need to be taken, but also have a better chance to appreciate their depth. And with those infiltrative tumors, it's much harder to really understand how to get that deep margin, which in many cases is always the hardest. And so that's a long way to say that surgical decision making, patient selection is really critical when it comes to offering TORS as a multidisciplinary group. And then there are a few other things that we can quickly talk about before we move on to discussing adjuvant therapy. But I think there are some relative contraindications to patients who might have tumors arising in a palatine tonsil or tonsillar pillar, but which might grow significantly into the soft palate, such that a major palatal resection would be needed to get a good margin. For T1 and T2 tumors, we're not sure that that is an ideal candidate. And the other relative contraindication, but it's a hard and fast contraindication in my personal practice, is patients with extensive nodal disease. I think a patient who has preoperative extranodal extension, matted nodes, clinically and on MRI, you know pre-op they're going to need intensive post operative concurrent chemoradiation post-op that's maybe not the best patient for TORS, although there are some select cases where that that might make sense. But that's a quick overview of patient selection for TORS, Brittany. Hopefully, that's helpful. Brittany Harvey: That's definitely helpful. I think it's really important to consider not only who is eligible, but who isn't eligible for this de-escalation of treatment, and I appreciate you clarifying some of that. So then you've just also mentioned adjuvant therapy along with multidisciplinary discussion. So what is recommended regarding adjuvant therapy for patients who have resected HPV-positive oropharyngeal squamous cell carcinoma? Dr. Chris Holsinger: Definitely. And I think the post-operative discussion has to begin with great pre-op planning. And pre-op planning is really anchored in a really robust multidisciplinary team. So, we spoke earlier about the critical importance of getting speech language pathology involved initially, but they're part of a much larger team that includes not just a surgeon, but medical oncologist, a radiation oncologist and a dental oncologist - all of these specialties, and I could think of several others if we had time to chat further - this should also be really engaged in the care of these patients. But great decision making regarding adjuvant therapy really begins with a robust multidisciplinary consultation pre-op and we try to emphasize that in the guidelines. But just to return and answer your question very directly, I think adjuvant therapy is really the critical piece in getting that great functional outcome for a patient with HPV-mediated throat cancer. And I think traditionally patients who have a variety of different risks, based on a large study done again by the ECOG group, ECOG 3311, we showed that by stratifying patients based on their surgical pathology rather than on an estimate of disease extent, we can better stratify adjuvant therapy. And so the low risk patient is a patient with good margins and of course, good margin, we could spend another two hours discussing that. But good margins are greater than at least 1 to 3 millimeters superficially and a clear deep margin. Patients with lymph node metastases that are less than 3 cm and a single lymph node can sometimes be observed but most patients don't fall into that low risk category. Most patients fall into an intermediate risk where the margin is good and it's clear, but it might be close. That depends if you're talking about the superficial mucosal margin or the deep. But more often than not, we spend a lot of time considering the extent of lymph node involvement as it pertains to how adjuvant therapy is delivered. And I think for patients with less than 4 lymph nodes traditionally without extranodal extension, radiation therapy will suffice for adjuvant therapy after TORS. And the question of dose then comes up. Are we talking 50 Gray, the experimental arm that showed real promise in the ECOG 3311 trial, or 60 Gray or more traditional dose? And that is a topic definitely for another podcast, which we should do with a radiation oncologist online. I don't want to get into the weeds with that, but I refer you to our guidelines and Bob Ferris and Barbara Burtness' paper from JCO in 2021 for further details about that. But then for patients with positive margins with more than four lymph nodes, but especially patients with extranodal extension, the role of radiation therapy and chemotherapy is really absolutely critical. Because these patients and while they only accounted for around 20% to 30% of patients that we're seeing in this new era of TORS, they're the ones that we're really focusing on how can we do better because their overall survival is still good, it's 90%, but it's not as good as the patients we're seeing with a low and intermediate risk. So that's a brief overview there. Brittany Harvey: I appreciate that overview. And yes, we'll refer listeners to the full guideline, which is linked in the show notes of this episode to learn more about the intricacies of the radiation therapy that you mentioned. So then we've talked a lot about patients with HPV-positive disease, but what is the role of TORS in patients with HPV-negative disease? Dr. Chris Holsinger: I think TORS still has a role for these patients. Our colleague in India, Surender Dabas, has a really nice series that shows that for HPV-negative patients, this is a way for early stage cancers to potentially escalate the intensity of treatment for a disease that does worse than this new HPV-positive we're seeing in the US. So I think there's a good signal there. I think more study needs to be done and I think those studies, in fact, are underway in India and other countries. I hope that we can, as an oncology community here in the United States, also tackle this disease, which is still a significant part of the disease we face in head and neck oncology. Brittany Harvey: Yes, we'll look forward to more data coming out for HPV-negative disease. So then, the last clinical question that the guideline panel addressed: What is the role of TORS in the salvage or recurrent setting? Dr. Chris Holsinger: So we wrap up the guidelines tackling this topic. It's definitely something for the experienced TORS surgeon in consultation with that multidisciplinary team. Oftentimes, we are still seeing many patients who need salvage surgery and I think, while TORS alone could be a really effective treatment option, TORS with a microvascular reconstruction is oftentimes what is needed for these patients who, with recurrence, do often present with an RT 2, 3, 4 tumor. In my own practice, I found that using TORS as a way to minimize the superficial mucosal extent and then delivering that tumor through a traditional lateral pharyngotomy, then neck dissection and then having a microvascular flap inset done after that really provides the best possible chance for good long term function and of course control of the tumor. Here, I definitely refer the listener to some great work done out of the Royal Marsden with Vin Paleri, who we're happy to have on our TORS guideline panel for his RECUT study that really grapples in some detail with these very issues. Brittany Harvey: Excellent. And so we've covered a lot of the recommendations here that were made by the panel and you've touched a little bit about how this changes things for clinicians in practice. But what should clinicians know as they implement these new recommendations? Dr. Chris Holsinger: One thing as we close, I hope that in the future we can really start to grapple with this concept of patient selection. I think these guidelines help establish that TORS is a great oncologic option with - really the only option for treatment de-escalation in the here and now. Radiation therapy and cisplatin concurrent chemotherapy is going to be an option that is such an important choice for patients. And I think where I hope the field goes in the future is figuring out which patient wants one of these options. And I think certain patients really want that tumor taken out and others just the idea of surgery is not something that makes sense for them. How we in the context of a multidisciplinary team, really engage that patient, elicit their treatment preferences and then through considering treatment eligibility criteria that we've spelled out here for surgery and can be spelled out for chemo RT, bringing all that together in a formal shared decision making process is really where I hope the field will be going in the next few years. And hopefully these guidelines help to pave the way there. Brittany Harvey: Definitely the aspect of care by a multidisciplinary team and talking with patients to go through shared decision making is key to implementing these guidelines. So then, in that same vein, what do these recommendations mean for patients with oropharyngeal squamous cell carcinoma? Dr. Chris Holsinger: I think the central take home message for patients should be that especially if you have a T1 and T2 tumor, it's really important to have that consultation with a surgeon who knows how to do TORS and has a busy practice, but then also having an honest discussion up front about what the functional outcomes would be both with surgery and also chemo RT. And I think just knowing all those different options, that multidisciplinary treatment selection process is going to be that much more robust. And I think more right decisions will get made and we'll see less decisional regret down the road, which I think is a long term goal of our field. Brittany Harvey: Absolutely. That discussion of preferences is key. So then to wrap us up, you touched on this a little bit earlier in talking about ongoing research and data, particularly in the field of HPV-negative disease, but what are the outstanding questions regarding TORS in this patient population? Dr. Chris Holsinger: Yeah, I think that in addition to this work around shared decision making, I really hope that we'll embrace shared decision making in the context of future clinical trial. I think where we are now is you have surgeons saying, “Hey, TORS and 50 gray is a great option. Why aren't we doing that?” And then our colleagues, perhaps across the aisle, if I can use a political metaphor, are saying, “Well, where's the comparative data? Can we even do a randomized clinical trial between surgery and radiation?” Well, Christian Simon in Lausanne in Switzerland is trying to do this in a small pilot study being led by the EORTC, and I would encourage American investigators to consider something analogous. But I think how we solve this question of I think treatment choice is going to be pivotal for any such trial to ever be done. And then finally, I think, how will the changing treatment landscape around immunotherapy change this? There's some really provocative data that dates back to 1996 in a JCO paper from Ollivier Laccourreye and the University of Paris experience that showed induction chemotherapy followed by function preserving surgery in the larynx was a really powerful strategy for organ preservation, and that has never been followed up in the United States. And so especially with the upcoming presentation of KEYNOTE-689, will we be doing neoadjuvant approaches for patients and then following them by minimally invasive surgery or lower dose radiation? I think these are going to be some exciting new areas of study and I can't wait to see how this might evolve so we can refine the treatment - still get those great outcomes, but reduce those late toxicity. Brittany Harvey: Yes. We'll look forward to this ongoing research to continue to move the field forward. So, Dr. Holsinger, I want to thank you so much for your time to develop this important guideline. It's been great to have you on the podcast to discuss it today. Dr. Chris Holsinger: Well, thanks a lot Brittany. It's nice to finally meet you. Brittany Harvey: Likewise. And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/head-neck-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.

Dr. Van Morris presents the new evidence-based guideline on systemic therapy for localized anal squamous cell carcinoma. Dr. Morris discusses the key recommendations from the Expert Panel, including recommended radiosensitizing chemotherapy agents, dosing and schedule recommendations, the role of induction chemotherapy and ongoing adjuvant chemotherapy, and considerations for special populations. He emphasizes the importance of this first guideline from ASCO on anal squamous cell carcinoma for both clinicians and patients with stage I-III anal cancer, and ongoing research the panel is looking to for the future. Read the full guideline, “Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline” at www.asco.org/gastrointestinal-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02120 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts, delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Van Morris from MD Anderson Cancer Center, co-chair on “Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.” Thank you for being here today, Dr. Morris. Dr. Van Morris: Thank you for having me. On behalf of our committee who put together the guidelines, I'm really excited to be here and talk with you today. Brittany Harvey: Great. Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Morris, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to jump into the content of this guideline, Dr. Morris, can you provide an overview of both the purpose and the scope of this guideline on stage I to III anal squamous cell carcinoma? Dr. Van Morris: So anal cancer is considered a rare malignancy for patients in the United States and across the world as well. Even though it's not something we see as commonly, for example, as the adjacent colorectal cancer, this still is a cancer that is rising in incidence every year in the United States. And really, despite the presence of the preventative HPV vaccines, which we hope will ultimately prevent and eradicate this cancer, we still expect the incidence to continue to rise in the coming decades before we really start seeing numbers begin to decrease as a result of the vaccine. So this is an alarming trend for which oncologists will continue to see likely more and more cases and new diagnoses every year. So we wanted to review the most recent literature and provide oncologists up to date recommendations for how they can best take care of patients with a new diagnosis of localized anal cancer. Brittany Harvey: Absolutely. I appreciate that background and context to set the stage for this guideline. So then next I'd like to review the key recommendations of this guideline. So starting from the first clinical question, what are the recommended radiosensitizing, doublet or single chemotherapy agents for patients with stage I to III anal cancer? Dr. Van Morris: It's true that really the standard treatment for patients with localized anal cancer has not changed over the last literally half century. When the Nigro regimen was first reported back in 1974, 50 years ago, the standard of care for patients with a new diagnosis of localized anal cancer centers around concurrent chemotherapy and radiotherapy. And we looked at the various randomized control trials and the highest level of evidence which has been reported over the past decades, and really for most patients, the standard of care continues to remain doublet cytotoxic chemotherapy in combination with radiation. We reported that the most commonly, and I think most accepted, regimen here is a combination regimen of 5-FU, intravenous 5-fluorouracil with mitomycin C. And this most commonly is given on a week 1 to 5 regimen. The 5-FU, we recommended a dose of 1000 milligrams per meter squared per day on days 1 to 4 and then on days 29 to 32 of the radiation treatment. And then the mitomycin C, looking at various trials, has been given at a dose of 10 milligrams per meter squared on day 1 and day 29, or alternatively a single dose of mitomycin C at 12 milligrams per meter squared on day 1. I think that the thing that's important for clinicians and patients alike to remember is that this chemotherapy can be very toxic in patients who are undergoing a curative-intent therapy for this diagnosis of localized anal cancer. I think it's just important for oncologists to be watching closely the blood counts for the patients to make sure that the myelosuppression doesn't get too bad. And then in select cases, if that is the case, when the oncologist opts to go for the day 1 and day 29 dosing, it may be prudent, if the myelosuppression is too excessive, to consider withholding that day 29 dose. Brittany Harvey: Great. Thank you for providing those recommendations along with some of those dosing and the schedule recommendations from the expert panel. So are there any other alternate dose or schedule recommendations from the expert panel? Dr. Van Morris: Yeah, but I think that we saw with the ACT II data that was a randomized trial that was done out of the UK that compared 5-FU mitomycin with 5-FU cisplatin as two different doublet cytotoxic regimens, that overall outcomes were very similar between the two regimens in terms of curative outcomes for patients treated whether 5-FU mitomycin or 5-FU cisplatin. So certainly there is evidence supporting the use of cisplatin as a second cytotoxic agent with 5-fluorouracil. In the ACT II study that was given at a dose of 60 milligrams per meter squared on days 1 and 29 along with the 5-FU at the regimen I talked about previously. There is other lower level of evidence data suggesting that even the 5-FU and cisplatin can be given on a weekly schedule and that that can be safe. Actually, at my institution at MD Anderson, that is our standard practice pattern as well. There's also the option when we're thinking about giving pelvic radiation for patients with lower GI cancers, many oncologists in the treatment of localized rectal adenocarcinoma are accustomed to using capecitabine as a chemosensitizer in patients with localized rectal cancer. If I'm giving chemoradiation for a patient with localized anal cancer, can I substitute the intravenous 5-FU with oral capecitabine? And although the evidence is not as strong in terms of available data with regards to randomized controlled trials, there certainly is data that suggests that capecitabine may be an acceptable alternative in lieu of intravenous 5-fluorouracil that would be given at a dose of 825 milligrams per meter squared on days of radiation. But certainly, I think that that's a feasible approach as well and maybe even associated with less hematologic toxicity than intravenous 5-FU would be. Brittany Harvey: Great. It's important to understand all the options that are out there for patients with early-stage anal squamous cell carcinoma. So in addition to those chemoradiation recommendations, what is recommended from the expert panel regarding induction chemotherapy or ongoing adjuvant chemotherapy for this patient population? Dr. Van Morris: When we think about treating patients with lower GI cancers with curative intent therapies, when we think about the more common rectal adenocarcinoma, oncologists may be used to giving chemoradiation followed by subsequent cytotoxic chemotherapy. But actually when you look at the data for anal cancer, really there's not any data that strongly supports the use of either induction chemotherapy prior to chemoradiation or adjuvant post-chemoradiation chemotherapy. The RTOG 98-11 study was a trial which evaluated the role of induction 5-fluorouracil prior to chemoradiation and did not show any survival benefit or improved outcomes with the use of induction chemotherapy in a randomized control trial setting. The ACT II trial, which I referenced earlier, was a 2 x 2 design where patients were either randomized to concurrent chemoradiation with 5-FU mitomycin C or concurrent chemoradiation with 5-FU cisplatin. But then there was a second randomization after chemoradiation where half of the study participants received adjuvant cisplatin 5-fluorouracil after completion of their chemo radiation, or the other half were randomized to the standard of care, which of course would be observation. And what that trial showed was that there was no added benefit with the addition of post-chemoradiation cytotoxic chemotherapy. So we look at these data and say that in general, for the general population of patients with localized stages I to III anal cancer, there really is no supporting data suggesting benefit of either induction chemotherapy or adjuvant chemotherapy. And to that end, really it's concurrent chemoradiation remains the standard of care at this time for patients with a new diagnosis of localized anal cancer. Brittany Harvey: Absolutely. It's just as important to know what is not recommended as it is to know what is recommended for these patients. And so I thank you for explaining the evidence behind that decision from the panel as well. So then, are there any other considerations for special populations that oncologists should consider? Dr. Van Morris: I think so. I think that anal cancer is a disease where we don't see that many patients being diagnosed earlier at a younger age, especially in relation to the alarming trend of early onset colorectal cancer that we're currently seeing right now. So there may be patients who come with a new diagnosis of localized anal cancer who are an octogenarian at an advanced age or may have other significant medical comorbidities. And if that is the case, we get called about this quite frequently from outside institutions. I have an 85 year old who is coming to my clinic with this diagnosis. I don't feel comfortable giving this patient doublet cytotoxics, what options do I have? Especially given other organ dysfunction that may precede this diagnosis. And I think that in that case, there are times when it's okay safely to drop the mitomycin C and opt for single agent 5-fluorouracil as a single cytotoxic agent. So I think that that would be something that we've certainly incorporated into our practice at our institution. There's also an association between various autoimmune disorders, patients on immunosuppression, even persons living with HIV being at higher risk for this virally associated cancer. So I think that, again, if the patient is coming with baseline immunosuppression for these reasons prior to treatment, certainly kind of being in tune to the potential for hematologic toxicity. And watching these patients very closely as they're getting chemoradiation remains really important. Brittany Harvey: Definitely. So, you've just discussed some of those comorbidities and patient characteristics that are important for clinicians to consider when deciding which regimens to offer. So in addition to those, in your view, what is the importance of this guideline and how will it impact clinical practice for clinicians who are reading this guideline. Dr. Van Morris: Chemoradiation remains a very effective option and most patients will be cured with this diagnosis and with this treatment. So it's important to make sure that these patients are able to safely get through their treatment, minimizing treatment delays due to toxicities which may come about because of the treatment, and really help to carry them over the finish line so that they have the best likelihood for achieving cure. So we really hope that these data will provide oncologists with a readily available summary of the existing data that they can refer to and continue to help as many patients as possible achieve and experience a cure. Brittany Harvey: Absolutely. So then to build on that, it's great to have this first guideline from ASCO on anal squamous cell carcinoma. But how will these new recommendations affect patients with stage I to III anal cancer? Dr. Van Morris: I certainly hope it will allow patients and oncologists to know what their options are. It certainly is not a one size fits all treatment approach with regards to the options which are available. Depending on the patient, depending on the various medical conditions that may accompany them, these treatments may need to be tailored to most safely get them through their treatment. Brittany Harvey: I appreciate you describing the importance of this guideline for both clinicians and patients. So what other outstanding questions and future research do you anticipate seeing in this field? Dr. Van Morris: It's a really good question and I think that there is a lot coming on the horizon. Even though the standard treatment has really not changed over the last half century, I think it still remains true that not all patients will achieve cure with a chemoradiation treatment. So a recent trial has completed enrollment in the United States, this is the EA2165 trial led by one of our committee members, Dr. Rajdev and Dr. Eng as well, that's looking at the use of nivolumab anti PD-1 immunotherapy after completion of concurrent chemo adiation. So in that trial, patients were randomized to concurrent chemoradiation followed by either observation or six months of adjuvant anti PD-1 therapy. We're really awaiting the results of that. Hopefully if we see an improvement with the addition of nivolumab following concurrent chemoradiation, our hope would be that more patients would be able to achieve a cure. So we're certainly looking forward to the outcomes of that EA2165 study. And then I think one question that we often get from our patients in the clinics is, “What is the role of circulating tumor DNA in the management of my disease?” And really, to date there have been some series which have shown that we can assess patients or circulating tumor DNA after completion of their concurrent chemo radiation that may need to start about three months after to give time for the radiation to wear off and most accurately prognosticate that. But I think that this will be a powerful tool moving forward, hopefully, not only in the surveillance to identify patients who may be at high risk for recurrence, but ultimately to translate that into next generation clinical trials which would treat patients at higher risk for recurrence by virtue of a detectable circulating tumor DNA result. In doing so, hopefully cure even more patients with this diagnosis. Brittany Harvey: Yes, we'll look forward to these developments and hope to add more options for potential treatment and surveillance for patients with anal cancer. So, I want to thank you so much for your work to develop these guidelines and share these recommendations with us and everything that the expert panel did to put this guideline together. Thank you for your time today, Dr. Morris. Dr. Van Morris: Thank you. And thank you to ASCO for helping to keep this information out there and ready for oncologists for this rare cancer. Brittany Harvey: Absolutely. And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.    

Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.

Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.

In this episode, we review the high-yield topic of ⁠Squamous Cell Carcinoma ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Nutrition section at ⁠⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠ Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Dr. Deborah Wong, Director of the Medical Oncology Program and Clinical Trials Program for Head and Neck Squamous Cell Cancers (HNSCC) and an Associate Clinical Professor of Medicine at the University of California Los Angeles (UCLA) is currently serving as co-chair of i3 Health's accredited CME/NCPD activity, Recurrent and Metastatic HNSCC, Harnessing Immunotherapy and Comprehensive Care. With new developments in the field occurring over recent months, Dr. Wong sat down with us again to share new updates in treatment and management of HNSCC. Click here for the full activity: https://i3health.com/course-information/hnscc-harnessing-immunotherapy-in-comprehensive-care

Lisa Manyon was diagnosed in 2017 with Squamous Cell Carcinoma at the base of her tongue. Two years prior to receiving her diagnosis, she received a divine appointment to write a book about healing with love. Lisa journaled about it, tucked it away, and had no idea why she would be given such an assignment. In 2017 Lisa was reminded of this as she navigated facing mortality, including a misdiagnosis that she refused to accept. She intuitively knew something BIG was going on and she pushed for the answers she needed to heal with love and become a cancer thriver. Lisa has been NED since 2017. Lisa is the author of Spiritual Sugar: The Divine Ingredients to Heal Yourself With Love Order your copy of Lisa's book, Spiritual Sugar at https://spiritualsugar.com For speaking and consulting inquiries for Lisa, visit WriteOnCreative.com ____________________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here. To purchase the full 10-epidsode Docuseries visit Hay House Online Learning. Click Here, to learn more about health coaching with Liz or Karla.   Follow us on Social Media: Facebook , Instagram, YouTube. ___________________ Thank you to our friends from The Healing Oasis for sponsoring this episode of the podcast.  The Healing Oasis is a first of its kind in beautiful British Columbia, Canada where we encourage the body to heal from cancer using alternative therapies & cancer fighting meals at a wellness retreat center in nature. Our top naturopathic cancer doctor will prescribe a protocol tailored specifically for you. There's no place quite like it. Start your healing journey today! Learn More about The Healing Oasis by visiting these links: Website   Testimonials Video Overview  

Interview with Kathryn T. Shahwan, MD, author of Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma: Expert Panel Guidelines from ITSCC. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma

Interview with Kathryn T. Shahwan, MD, author of Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma: Expert Panel Guidelines from ITSCC. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma

Guest: Lori J. Wirth, MD Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston. References: Gormley M, et al. Br Dent J. 2022;233(9):780-786. Barsouk A, et al. Med Sci (Basel). 2023;11(2):42. ©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.US-NONO-00581 05/2024

Comprehensive, relevant and insightful conversations about health and medicine from the largest healthcare system in the Maryland D.C. region: this is MedStar Health DocTalk.In our latest podcast episode, host Debra Schindler talks with thoracic surgeon Dr. Duane Monteith and gastroenterologist Dr. Dana Sloan for a comprehensive look into esophageal cancer. They discuss everything from early symptoms and risk factors to advanced treatment options like minimally invasive surgery. This episode is packed with valuable insights that could make a significant difference in early detection and treatment. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Please visit answersincme.com/PQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in squamous cell carcinoma of the head and neck (SCCHN) discusses the clinical potential of antagonists of inhibitor of apoptosis proteins (IAPs) for unresected, locally advanced SCCHN. Upon completion of this activity, participants should be better able to: Identify the rationale for investigating the use of antagonists of inhibitor of apoptosis proteins (IAPs) in the treatment of unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN); Discuss the latest efficacy and safety data for emerging IAP antagonists for the treatment of unresected LA SCCHN; and Outline clinical considerations for future use of IAP antagonists in unresected LA SCCHN.

Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

You have a patient referred to you for a history of anal dysplasia and found to have an anal lesion on colonoscopy. How do you evaluate this? What are the risk factors? How will you perform surveillance afterwards? Does everyone need HRA? Tune in to find out! Join Drs. Peter Marcello, Jonathan Abelson, Tess Aulet and special guest Dr. Lisa Breen as they discuss high yield papers discussing Anal Dysplasia.  Learning Objectives 1. Describe the different types of anal dysplasia and pathologic categorization 2. Describe high risk populations for development of anal squamous cell cancer 3. Discuss the different options and recommendations for surveillance and treatment of anal dysplasia Video Link: https://www.youtube.com/watch?v=YdOjV1Gcqvk **Introducing Behind the Knife's Trauma Surgery Video Atlas - https://app.behindtheknife.org/premium/trauma-surgery-video-atlas/show-content The Trauma Surgery Video Atlas contains 24 scenarios that include never-before-seen high-definition operative footage, rich, original illustrations, and practical, easy-to-read pearls that will help you dominate the most difficult trauma scenarios. ***Fellowship Application - https://forms.gle/5fbYJ1JXv3ijpgCq9*** Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out more recent episodes here: https://app.behindtheknife.org/listen

The saying "saving your skin" takes on extra meaning when you are outdoors. Living a "sun and fun" lifestyle can come with a price -- the sun's damaging UV rays and the risk of skin cancer. Hopefully, you practice safety by using sunscreens, hats and clothing to mitigate those harmful rays. Some people forget that sun damage and skin cancer can be synonymous. As spring and summer approach, how do we avoid skin cancer? And if it leaves a concerning spot on the skin, what do we do next? Host: Jonathan Fialkow, M.D., Chief Medical Officer at Baptist Health who oversees Population Health, Primary Care, Cardiology, Endocrinology and other Medical Specialties Guest: Michael Raish, M.D., Mohs Micrographic Surgeon and Dermatologist, Baptist Health Miami Cancer Institute 

Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

SHOW NOTES 0:55 - Contextual introduction for this episode's unique features 3:20 – Sample DJ clips 4:15 – Guest introduction 5:05 – Cancer, voice change, a long stint behind the high school football stadium game night microphone 6:00 – Rick starts his three-decades of announcing Friday night home games 7:55 – Son Rowdy follows Dad Rick at the football field 8:45 – Family members want to hear the players' names 10:30 – Daughter Grace, a performance from the (very) early years 12:00 – David (Reynolds) stands in for Brad Pitt 13:25 – Wife Margaret makes a huge difference in the community 15:55 – The story behind Be Nice to Grace Day 21:05 – Jeanne Burr (and Walter Hooper) as a catalyst for Rick on the air for the first time (at age 17) 24:45 – Listening to Chicago's AM station WLS 27:00 – John Records Landecker 30:00 – A lesson learned about making others feel important 32:24 – Interviewing Garth Brooks 33:40 – The first time cancer rears its head 39:30 – Focused radiation, bolted to the table, and a special mask 43:10 – Jimmy Buffet embedded in a family tradition 44:40 – Cancer reappears – in a new location 46:00 – Friend Amy's powerful question 46:40 – God's gameplan for Rick 49:45 – Lydia, a face from the past, and a new connection for the future 52:35 – High school reunion delays 54:10 – Living in a small town, great friends, great community 58:00 – Sharing one's story to give others hope 59:40 – A lesson Rick wants us to hear 1:04:40 – One of many similar stories of good fortune – Running out of gas on I-75 North 1:07:00 – A mini-facelift's role in the past twenty years of Rick's life 1:07:50 – The most recent doctor's visit and current prognosis 1:09:40 – The unexpected result of Rick losing his voice  LINKS:Instagram: @therickontheradioJohn Records LandeckerEmory Proton CenterRowdy Zeisig, the new Dalton High School football announcerJeanne BurrDunaway Drug StoreBeaulieu's beginningJimmy Buffet's 'Twas the Night Before ChristmasMusic for Lead. Learn. Change. is Sweet Adrenaline by Delicate BeatsPodcast cover art is a view from Brunnkogel (mountaintop) over the mountains of the Salzkammergut in Austria, courtesy of photographer Simon Berger, published on www.unsplash.com.Professional Association of Georgia EducatorsDavid's LinkedIn page 

In this week's New FDA Approval's podcast episode, Dr. Emma Hitt Nichols discusses the latest FDA approvals from September 18, 2023 – September 22, 2023.  Please check back every Monday morning so that you can stay up to date.  Check out our free downloads at nascentmc.com: Implementing AMA Style – 8 Things to Get Right in Your Next Project Needs Assessments – 7 Essentials for Getting Funded Working With Your Medical Writer – 8 Ways to Get the Most out of Them See more details summaries and links to prescribing information at nascentmc.com/podcast Here are the highlights: Jardiance (empagliflozin) for CKD  The FDA has approved Jardiance, an SGLT2 inhibitor, for patients with end-stage kidney disease, speciifically to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. The approval is based on the EMPA-KIDNEY phase 3 trial, demonstrating a significant reduction in kidney disease progression and cardiovascular death compared to a placebo.  Welireg (belzutifan) for Advanced Renal Cell Carcinoma The FDA granted Priority Review for Merck's Welireg for advanced renal cell carcinoma post other treatments. Welireg, a HIF-2α inhibitor, is being evaluated in the LITESPARK-005 trial, where it was compared with everolimus for advanced RCC treatment post PD-1/L1 or VEGF-TKI therapies. Tevimbra (tislelizumab) for Esophageal Squamous Cell Carcinoma The FDA is reviewing an application for Tevimbra for treating advanced or metastatic esophageal squamous cell carcinoma. Supported by the phase 3 RATIONALE 306 study, the drug improves overall survival rates when combined with chemotherapy in these patients. Neffy Epinephrine Nasal Spray The FDA rejected the approval of Neffy, a needle-free nasal spray for allergic reactions. Despite a positive Advisory Committee vote, the FDA demands further testing. ARS Pharmaceuticals plans to re-submit its application and appeal the decision in 2024.  Intro and outro music Garden Of Love by Pk jazz Collective

This is a recap of the top 10 posts on Hacker News on July 22nd, 2023.This podcast was generated by wondercraft.ai(00:38): I am dying of squamous cell carcinoma, and potential treatments are out of reachOriginal post: https://news.ycombinator.com/item?id=36827438&utm_source=wondercraft_ai(02:27): Plane – Open-source Jira alternativeOriginal post: https://news.ycombinator.com/item?id=36824450&utm_source=wondercraft_ai(04:13): Shopify employee breaks NDA to reveal firm replacing laid off workers with AIOriginal post: https://news.ycombinator.com/item?id=36828409&utm_source=wondercraft_ai(06:00): FBI improperly used 702 surveillance powers on US senatorOriginal post: https://news.ycombinator.com/item?id=36822654&utm_source=wondercraft_ai(07:45): Putting the “You” in CPUOriginal post: https://news.ycombinator.com/item?id=36823605&utm_source=wondercraft_ai(09:13): Compromised Microsoft key: More impactful than we thoughtOriginal post: https://news.ycombinator.com/item?id=36823007&utm_source=wondercraft_ai(11:18): A Caltech Nobel laureate celebrates his 100th birthday, then gets back to workOriginal post: https://news.ycombinator.com/item?id=36828811&utm_source=wondercraft_ai(13:07): AWS networking concepts in a diagramOriginal post: https://news.ycombinator.com/item?id=36823516&utm_source=wondercraft_ai(14:53): Important Coding HabitsOriginal post: https://news.ycombinator.com/item?id=36826755&utm_source=wondercraft_ai(16:38): What we talk about when we talk about system designOriginal post: https://news.ycombinator.com/item?id=36823375&utm_source=wondercraft_aiThis is a third-party project, independent from HN and YC. Text and audio generated using AI, by wondercraft.ai. Create your own studio quality podcast with text as the only input in seconds at app.wondercraft.ai. Issues or feedback? We'd love to hear from you: team@wondercraft.ai